Arvinas Inc (ARVN) Stock Analysis
Verdict: AVOID
Severe cash burn creates an urgent ~6-month runway constraint, making heavy dilution or trial binary outcomes the sole price drivers.
Investment score: 30/100
Analysis as of
Is Arvinas Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assigns an AVOID rating to Arvinas Inc. due to an acute balance sheet runway limit (~6 months remaining at 2025 cash burn rates) and persistent high insider selling.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Arvinas Inc opportunities and risks
What speaks for ARVN
- Pfizer partnership on vepdegestrant validates the PROTAC degradation platform
What speaks against ARVN
- Imminent equity dilution required due to a critical ~6-month cash runway
Frequently asked questions about Arvinas Inc (ARVN)
Is ARVN stock a good investment?
The TradeMates model rates Arvinas Inc as AVOID with an investment score of 30/100. The TradeMates model assigns an AVOID rating to Arvinas Inc. due to an acute balance sheet runway limit (~6 months remaining at 2025 cash burn rates) and persistent high insider selling. This is algorithmic model output, not personal investment advice.
Is ARVN stock a buy?
The TradeMates model verdict for ARVN is AVOID with an investment score of 30/100. Treat this as a model signal to review, not a personal buy recommendation.